Name: Protalix BioTherapeutics, Inc. (DE) (PLX) — quotes and trading statistics
Creator: TradeAlmanac
License: https://tradealmanac.com/en/sources

TradeAlmanac

Loading the list…

Multiples: Protalix BioTherapeutics, Inc. (DE) (PLX) — TradeAlmanac

Company valuation

Market capitalisation: 227M $
Price / earnings: 12.0sector median 25.8
Price / sales: 2.8sector median 3.7
Price / book: 3.2sector median 2.3
Return on equity: 26.53%sector median −40.58%
Return on assets: 17.17%sector median −30.08%
Net margin: 23.50%sector median −20.85%
Operating margin: 28.89%sector median −20.96%
Current ratio: 2.9
Revenue, last year: 81M $
Net income, last year: 19M $
Earnings per share: $0.23
Revenue growth, year over year: +30.14%sector median 7.81%

Based on the last 12 months of reports, through 30 June 2026

The sector median covers every company in the sector on the US market, loss-making ones included.

How to read the figures

Market capitalization is the value of all of a company's shares at the current price: the price of one share times the number of shares.
P/E (price / earnings) is the share price divided by earnings per share over the last 12 months — roughly the number of years of current profit the price is worth. It is not calculated for loss-making companies.
P/S (price / sales) is market capitalization divided by revenue over 12 months: what the market pays for each unit of sales. Useful when there is no profit yet.
P/B (price / book) is market capitalization divided by shareholders' equity: below one means the market values the company under its accounting assets net of debt.
ROE (return on equity) is net income over 12 months divided by shareholders' equity: how much profit the company earns on each unit of its owners' capital.
ROA (return on assets) is net income divided by total assets: how efficiently the company uses what it owns.
Net margin is the share of net income in revenue: how much profit remains from each unit of sales.
Operating margin is the share of profit from core operations in revenue, before interest and taxes.
The current ratio is current assets divided by short-term liabilities: whether the company has enough cash and inventory to pay its nearest debts.
Revenue growth is the change in revenue over the last 12 months against the same period a year earlier.

Protalix BioTherapeutics, Inc. (DE) (PLX)

Related instruments

Company valuation

Related instruments

Protalix BioTherapeutics, Inc. (DE) (PLX)

Chart

Company valuation

Related instruments